Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval
Abstract Zavegepant is a novel gepant administered as a nasal spray approved in the United States at a 10 mg dose for the acute treatment of migraine with or without aura in adults. The cardiovascular safety of zavegepant nasal spray was assessed in both single‐ascending dose (SAD) and multiple‐asce...
Saved in:
Main Authors: | Jim H. Hughes (Author), Richard Bertz (Author), Rajinder Bhardwaj (Author), Mary K. Donohue (Author), Jennifer Madonia (Author), Matt S. Anderson (Author), Beth A. Morris (Author), Robert S. Croop (Author), Jing Liu (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects
by: Rajinder Bhardwaj, et al.
Published: (2024) -
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
by: Rajinder Bhardwaj, et al.
Published: (2024) -
FDA APPROVED THE FIRST NASAL SPRAY WITH ADRENALINE TO ELIMINATE ANAPHYLAXIS
by: article Editorial
Published: (2024) -
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
by: Rajinder Bhardwaj, et al.
Published: (2024) -
No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
by: Song Mu, et al.
Published: (2020)